Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 480pembrolizumab 455Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 314Cisplatin 271Biopsy 271Radiotherapy 244Paclitaxel 229Gemcitabine 227Bevacizumab 213Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Blood Specimen Collection 158Dexamethasone 157Oxaliplatin 154Injections 152Capecitabine 151Fluorouracil 144Docetaxel 144Radiosurgery 137Standard of Care 135Rituximab 125Pemetrexed 117durvalumab 115Leucovorin 109atezolizumab 107Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Tirapazamine × 1 year × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡